memantine


Also found in: Medical, Wikipedia.

me·man·tine

 (mə-măn′tēn)
n.
A drug, C20H24N5O4, used in its hydrochloride form to treat symptoms of Alzheimer's disease by inhibiting NMDA receptors.

[me(thyl) + (ada)mant(ane), molecule with a diamond-like structure (from Greek adamās, adamant-, diamond; see adamant) + -ine.]
Translations

memantine

n memantina
References in periodicals archive ?
It also recommended the use of memantine (Ebixa, Lundbeck) for severe disease and for some patients with moderate disease.
Dr David Wilkinson, consultant in Old Age Psychiatry at the Memory Assessment and Research Centre in Southampton commented: "This decision from NICE is very welcome news as memantine, with its different mode of action from the other available treatments, offers new hope for patients, carers and doctors dealing with Alzheimer's disease - one of the most distressing diseases we have to face.
Brennan, from McLean Hospital in Belmont, Massachusetts, said his team was not surprised that memantine reduced binge episodes since that was their initial hypothesis.
1-3) Derived from the older drug amantadine, memantine dampens output from the subthalamic nucleus, potentiates dopamine release and attenuates degeneration of dopaminergic neurons.
50 daily cost of Memantine, sold as Ebixa, ahead of the lives of sufferers.
50 daily cost of Memantine ahead of the lives of sufferers.
approval in 2003, the drug memantine has been prescribed to slow mental decline in people with moderate-to-advanced Alzheimer's disease.
Barbara Olivan-Blazquez of the University of Zaragoza, Spain, and colleagues evaluated the efficacy of memantine for pain symptom control in fibromyalgia (Pain.
Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Memantine Hydrochloride Oral Solution 2 mg/mL, the therapeutic similar to the reference listed drug Namenda Oral Solution, 2 mg/mL of Forest Pharmaceuticals.
Any such statement, including, but not limited to, successfully commercializing Memantine Hydrochloride Oral Solution 2 mg/mL, whether expressed or implied, is subject to market and other conditions, and subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated due to a number of factors which include, but are not limited to, the risk factors discussed in the Company's Form 10-K and other documents filed with the SEC from time to time, including the prospectus supplement related to the proposed offering to be filed with the SEC.
NEW ORLEANS -- The combination of memantine and a cholinesterase inhibitor improved behavioral symptoms in patients with moderate-severe Alzheimer's dementia, according to two pooled, post hoc analyses.
University School of Medicine demonstrates that an Alzheimer's drug called memantine may reduce the impulse to binge eat by acting on an area of brain associated with addictive behavior.